Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dimerix Limited ( (AU:DXB) ) has provided an update.
Dimerix Limited announced that its lead asset, DMX-200, has received Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. This designation provides significant benefits such as financial incentives, regulatory assistance, and market exclusivity, enhancing the commercial potential of DMX-200. The Phase 3 clinical trial, ACTION3, is currently recruiting in Japan, and Dimerix’s commercial partner, FUSO Pharmaceutical Industries, has exclusive rights to develop and commercialize DMX-200 in Japan. The designation marks a major milestone for Dimerix’s global strategy to provide new treatment options for FSGS patients.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.46 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory diseases, including kidney and respiratory diseases. The company is advancing its proprietary Phase 3 product candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) and DMX-700 for respiratory disease. Dimerix utilizes its proprietary Receptor Heteromer Investigation Technology (Receptor-HIT) to identify new drug opportunities.
Average Trading Volume: 1,430,179
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$306.1M
For an in-depth examination of DXB stock, go to TipRanks’ Overview page.